Connective Tissue Disease Patients With Pulmonary Hypertension
Trial statusNot yet recruiting
Trial phaseNot listed
Trial typeObservational
Biological sexAll
Age18-75
SponsorThe First Affiliated Hospital with Nanjing Medical University
About this trial
Adult patients with suspected or confirmed Connective Tissue Disease Patients (CTD)With Pulmonary Hypertension(PH)will be recruited. Patients will be approached, consented, have baseline demographics, diagnostics and disease activity measures recorded, and blood taken. The collection of data and biological material will mirror usual clinical practice as far as possible. Subjects will ideally attend further visits at 3, 6 and 12 months to have bloods taken, outcome measures recorded and questionnaires completed.
Eligibility criteria
This trial accepts healthy volunteersQualifiers
Definite diagnosis of CTD included Systemic lupus erythematosus（SLE） diagnosed according to the 2019 The European Alliance of Associations for Rheumatology（EULAR） criteria, primary Sjogren's syndrome (pSS) defined according to the 2016 American College of Rheumatology(ACR) criteria, Systemic Sclerosis(SSc) defined according to the 2013 ACR criteria, mixed connective tissue disease (MCTD) defined by Sharp criteria, and Rheumatoid Arthritis(RA) defined according 2010 ACR criteria of two or more CTD at the same time were defined as having overlap syndrome (OS). Patients who had clinical and serological manifestations suggestive of systemic autoimmune diseases but did not fulfil the classification criteria for CTD were defined as having undifferentiated CTD (UCTD).
PAH was diagnosed by right heart catheterization was defined as mean Pulmonary Artery Pressure (mPAP)>20 Millimeters of mercury（mmHg）, Pulmonary Artery Wedge Pressure（PAWP）≤15mmHg, Pulmonary Vascular Resistance（PVR）>2 Wood
Disqualifiers
significant interstitial lung disease or chronic obstructive pulmonary disease;
left heart disease or congenital heart disease associated with pulmonary hypertension;
chronic thromboembolic pulmonary hypertension;
portal hypertension;
Trial population
Connective Tissue Disease Patients With Pulmonary Hypertension
Trial design
Design model
Cohort
Time perspective
Prospective
Treatments tested in this trial
No Intervention
Other interventionNo Intervention
Treatment groups
500 Participants
are divided into 3 treatment groupsGroup A: Connective Tissue Disease Patients With Pulmonary Hypertension1 intervention
Group B: Connective Tissue Disease Patients Without Pulmonary Hypertension1 intervention
Group C: healthy1 intervention
Trial outcomes
Primary outcomes
1
Death
number of participants with All cause death
Time frame
30 yearsSecondary outcomes
1
Clinical worsening
number of participants with Hospitalization for worsening pulmonary arterial hypertension(PAH),lung or heart/lung transplant) or unsatisfactory long-term clinical response (the 6-minute walk distance decreased \> 15% from baseline and World Health Organization(WHO) functional class III/IV symptoms assessed at two clinic visits separated by \> 6 months after sufficient PAH targeted drug treatment.
Time frame
30 yearsLocations
Sponsors and contacts
Click on the lead sponsor to view all of their trials.
Source ClinicalTrials.gov
This trial is not recruiting at the moment. You can still explore other options: